Starpharma Holdings (SPL)

Download button icon Download

Starpharma Holdings (SPL): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Starpharma Holdings (SPL.AX)


Indicator:

RATE OF CHANGE


Last Signal:

BULLISH CROSSOVER


Trading: BUY @ $1.08
Signal Strength: MEDIUM
Recommendation:

Starpharma Holdings (ASX:SPL) currently has positive rate of change of 0.465%. This means the current price is greater than the price 14 days ago and therefore gaining momentum.

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement


Rate of Change (ROC) is a refinement of Momentum - readings fluctuate as percentages around the zero line. The indicator is designed for use in ranging markets - to detect trend weakness and likely reversal points. However when combined with a trend indicator it can be used in trending markets.

Calculation: Rate of Change (ROC):
1) (Closing Price [today] - Closing Price [n days ago]) / Closing Price [n days ago] * 100


PROFILE: Starpharma Holdings (SPL.AX)


Stock Exchange: ASX
Company: Starpharma Holdings
Ticker Codes: | SPL.AX | ASX:SPL |

About Starpharma Holdings (ASX:SPL):

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia and Canada. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections. It also develops dendrimer-enhanced, or DEP versions of existing drugs, including DEP docetaxel that is in Phase I clinical trial for breast, prostate, lung, and ovarian tumor. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Top 10:

Rate of Change

Download button icon Download
Company Close Change (%) Volume Value Signal
AGG Anglogold Ashanti 4.16 8.3 21,558 8.62 BULLISH CROSSOVER
RSG Resolute Mining 1.15 6.5 9,128,506 1.77 BULLISH CROSSOVER
AYS Amaysim Australia 0.95 5.6 94,182 2.15 BULLISH CROSSOVER
GSW Getswift 0.48 4.3 174,155 1.05 BULLISH CROSSOVER
EQT Equity Trustees 24.75 4 3,285 0.69 BULLISH CROSSOVER
ASG Autosports 1.03 3 1,250 5.1 BULLISH CROSSOVER
OCL Objective Corporation 2.6 2.8 538 0.39 BULLISH CROSSOVER
PMC Platinum Capital 1.73 2.4 366,198 0.58 BULLISH CROSSOVER
AMP AMP 2.27 2.3 19,538,735 0.44 BULLISH CROSSOVER
DTL Data#3 1.64 2.2 169,028 2.19 BULLISH CROSSOVER
back to top